A composition including adult pluripotent olfactory stem cells is provided. The adult pluripotent olfactory stem cells are obtained by culturing a cell mixture from an olfactory tissue of a mammal in media containing growth factors and then isolating cells which express B-lymphoma moloney murine leukemia virus insertion region-1 (Bmi-1).

The present invention relates in part to methods for producing tissue-specific cells from patient samples, and to tissue-specific cells produced using these methods. Methods for reprogramming cells using RNA are disclosed. Therapeutics comprising cells produced using these methods are also disclosed.

A method is presented for reprogramming cells of a subject. As a starting point, a biological sample of a sample cell is received from the subject, where the sample cell has a given cell type. The method includes: determining gene expression data for the sample cell from the biological sample; receiving gene expression data for a target cell having a target cell type, where the target cell type differs from the given cell type; deriving a state transition matrix which models cell dynamics; computing a regulatory set for a given transcription factor, where the regulatory set quantifies influence of the given transcription factor on a genome; expressing reprogramming of the sample cell to the target cell with a state-space representation of a linear system; and solving for the input vector in the state-space representation.

The current invention concerns a method for obtaining a cellular composition comprising epithelial stem cells (EpSCs) from mammalian skin, whereby said composition comprises at least 90% of viable EpSCs, comprising the steps of: obtaining a mammalian skin sample; obtaining a cell suspension from said skin sample by performing at least one enzymatic dissociation step; and culturing said cell suspension under low-attachment conditions. Preferably cellular composition comprises epithelial stem cells derived from the epidermal layer. In a second aspect, the current invention provides for a cellular composition obtained by the method according to the invention.

The present invention relates in part to methods for producing tissue-specific cells from patient samples, and to tissue-specific cells produced using these methods. Methods for reprogramming cells using RNA are disclosed. Therapeutics comprising cells produced using these methods are also disclosed.

The present invention discloses a method of inducing and differentiating human skin-derived precursors into corneal endothelial-like cells. The present invention utilizes human skin-derived precursors to induce corneal endothelial-like cells that are theoretically close to normal human corneal endothelial cells successfully by co-culturing with B4G12 corneal endothelial cells. Furthermore, the obtained corneal endothelial-like cells are applied to a corneal endothelial decompensation animal model, and corneal endothelium of the animal is successfully repaired, which has an important clinical application prospect.

The present invention provides a method for inducing an inversion of normal blood coagulation factor VIII (F8) gene, a method for correcting an inversion of blood coagulation factor VIII gene in which the inversion has occurred, and a Hemophilia A patient-derived induced pluripotent stem cell in which the inversion is corrected, constructed using the same. The method of the present invention effectively reproduces the inversion of intron 1 and intron 22 of the F8 gene, which is responsible for the majority of severe hemophilia A, and thereby may be effectively used for studying the development mechanism of hemophilia A and as a research tool for screening therapeutic agents. The inversion-corrected induced pluripotent stem cell constructed according the method of the present invention enables an efficient and fundamental treatment for hemophilia A by restoring a genotype in which mutation has occurred to a wild type-like state, without limitation via normal gene or protein delivery.

The present invention provides a method for inducing an inversion of normal blood coagulation factor VIII (F8) gene, a method for correcting an inversion of blood coagulation factor VIII gene in which the inversion has occurred, and a Hemophilia A patient-derived induced pluripotent stem cell in which the inversion is corrected, constructed using the same. The method of the present invention effectively reproduces the inversion of intron 1 and intron 22 of the F8 gene, which is responsible for the majority of severe hemophilia A, and thereby may be effectively used for studying the development mechanism of hemophilia A and as a research tool for screening therapeutic agents. The inversion-corrected induced pluripotent stem cell constructed according the method of the present invention enables an efficient and fundamental treatment for hemophilia A by restoring a genotype in which mutation has occurred to a wild type-like state, without limitation via normal gene or protein delivery.

Provided herein according to some embodiments is a method for producing an induced neural stem cell (iNSC), which method may include one or more of the steps of: providing a somatic cell; introducing into (e.g., by transfecting or transducing) said somatic cell with a nucleic acid encoding Sox2, whereby said cell expresses Sox2; and then transdifferentiating said somatic cell (e.g., by growing the cell in a neural progenitor medium), to thereby make said induced neural stem cell. In some embodiments, the transdifferentiating is carried out for a time of from 1 to 10 days, from 1 to 5 days, from 1 to 3 days, or from 12 to 24 or 48 hours.

The present invention relates in part to methods for producing tissue-specific cells from patient samples, and to tissue-specific cells produced using these methods. Methods for reprogramming cells using RNA are disclosed. Therapeutics comprising cells produced using these methods are also disclosed.